Cointime

Biostar Technologies

company

About

Biostar Technologies focuses in medical design, transfer of technology, and tech support advising for anti-tumor small chemicals drugs.

  • 11 - 50

Highlights

Total Funding Amount
$890M
Funding Rounds
2
Investors
3

Details

Last Funding Type
Series B
Industries
Biotechnology,Life Science,Medical,Pharmaceutical
Founded date
Jan 1, 2002
Number Of Employee
11 - 50
Operating Status
Active

Beijing Biostar Technologies, Ltd. was incorporated in Haidian Park, Zhongguancun Science and Technology Park, Beijing, in July 2002. The national high-tech led by the team of Chinese scientists in the United States led by Dr. Tang Li and Dr. Qiu Rongguo. The company, focusing on biomedical development, technology and transfer of anti-tumor small molecule chemical drugs, and technical service consulting, pioneered the creation of new anti-cancer drugs for epothilone in China, and its technology is at the international advanced level.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$890M
Biostar Technologies has raised a total of $890M in funding over 2 rounds. Their latest funding was raised on Nov 26, 2020 from a Series E round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Nov 26, 2020 Series E $890M 2 — — Detail
Feb 19, 2019 Series B — 1 — — Detail

Investors

Number of Lead Investors
Number of Investors
—
3
Biostar Technologies is funded by 3 investors. Chengdu Biocity and Tianchuang Capital are the most recent investors.
Investor Name Lead Investor Funding Round
Chengdu Biocity — Series E
Tianchuang Capital — Series E
Chengdu Venture Capital — Series B
Cointime
เนื้อหา
บริษัท